Unknown

Dataset Information

0

Hepatitis C–associated late-onset schizophrenia: a nationwide, population-based cohort study


ABSTRACT:

Background:

Whether infection with the hepatitis C virus (HCV) causes schizophrenia — and whether the associated risk reverses after anti-HCV therapy — is unknown; we aimed to investigate these topics.

Methods:

We conducted a nationwide, population-based cohort study using the Taiwan National Health Insurance Research Database (TNHIRD). A diagnosis of schizophrenia was based on criteria from the International Classification of Diseases, 9th revision (295.xx).

Results:

From 2003 to 2012, from a total population of 19 298 735, we enrolled 3 propensity-score-matched cohorts (1:2:2): HCV-treated (8931 HCV-infected patients who had received interferon-based therapy for ≥ 6 months); HCV-untreated (17 862); and HCV-uninfected (17 862) from the TNHIRD. Of the total sample (44 655), 82.81% (36 980) were 40 years of age or older. Of the 3 cohorts, the HCV-untreated group had the highest 9-year cumulative incidence of schizophrenia (0.870%, 95% confidence interval [CI] 0.556%–1.311%; p < 0.001); the HCV-treated (0.251%, 95% CI 0.091%–0.599%) and HCV-uninfected (0.118%, 95% CI 0.062%–0.213%) cohorts showed similar cumulative incidence of schizophrenia (p = 0.33). Multivariate Cox analyses showed that HCV positivity (hazard ratio [HR] 3.469, 95% CI 2.168–5.551) was independently associated with the development of schizophrenia. The HCV-untreated cohort also had the highest cumulative incidence of overall mortality (20.799%, 95% CI 18.739%–22.936%; p < 0.001); the HCV-treated (12.518%, 95% CI 8.707%–17.052%) and HCV uninfected (6.707%, 95% CI 5.533%–8.026%) cohorts showed similar cumulative incidence of mortality (p = 0.12).

Limitations:

We were unable to determine the precise mechanism of the increased risk of schizophrenia in patients with HCV infection.

Conclusion:

In a population-based cohort (most aged ≥ 40 years), HCV positivity was a potential risk factor for the development of schizophrenia; the HCV-associated risk of schizophrenia might be reversed by interferon-based antiviral therapy.

SUBMITTER: Cheng J 

PROVIDER: S-EPMC8565883 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5291589 | biostudies-literature
| S-EPMC7922671 | biostudies-literature
| S-EPMC6915266 | biostudies-literature
| S-EPMC4133657 | biostudies-literature
| S-EPMC7374233 | biostudies-literature
| S-EPMC526116 | biostudies-other
| S-EPMC7275510 | biostudies-literature
| S-EPMC4591281 | biostudies-literature
| S-EPMC7008294 | biostudies-literature
| S-EPMC8198559 | biostudies-literature